Oppenheimer Upgrades Relay Therapeutics to Outperform, Announces $14 Price Target
Benzinga Newsdesk 9 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Oppenheimer analyst Matthew Biegler upgrades Relay Therapeutics (NASDAQ:RLAY) from Perform to Outperform and announces $14 price target.
Oppenheimer analyst Matthew Biegler upgrades Relay Therapeutics (NASDAQ:RLAY) from Perform to Outperform and announces $14 price target.